Norsworthy KJ, Bird ST, Avagyan A, et al. Second cancers in adults with acute promyelocytic leukemia (APL) treated with or without arsenic trioxide (ATO): a SEER-Medicare analysis [abstract]. Blood. 2019;134(suppl 1). Abstract 3497.

In the original version of 2019 American Society of Hematology Annual Meeting abstract 3497, the following errors were present. In the table, some of the cells under “IV APL Chemotherapy” and “Second Malignancies” contained data about fewer than 11 patients. This was not in conformity with data use agreements with the National Cancer Institute (NCI) and the Centers for Medicare and Medicaid Services. In Figures 1 and 2, information about numbers of patients at risk at each time point was shown, but the NCI requested its removal. Before the Annual Meeting, the table was updated to display the data in a form that is compliant with the data use agreements and both figures were updated to omit the data for sample sizes at each time point. The corrected table and figures are shown below.